Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 19/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13642559 | 0.93 | IL23R (0.61) | IL23R | |
| SCHEMBL13881440 | 0.93 | IL23R (0.64) | IL23RRXFP1 | |
| SCHEMBL30138570 | 0.90 | IL23R (0.59) | IL23RRXFP1 | |
| SCHEMBL13881774 | 0.89 | IL23R (0.64) | IL23R | |
| SCHEMBL9551340 | 0.88 | IL23R (0.55) | IL23RRXFP1 | |
| SCHEMBL9551338 | 0.88 | IL23R (0.57) | IL23RRXFP1 | |
| SCHEMBL29396822 | 0.86 | NPBWR1 (0.61) | IL23RRXFP1 | |
| SCHEMBL30044926 | 0.86 | RXFP1 (0.60) | IL23RRXFP1 | |
| SCHEMBL12026380 | 0.85 | IL23R (0.68) | IL23RRXFP1 | |
| SCHEMBL12026379 | 0.85 | IL23R (0.68) | IL23RRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090110662-A1 | MODIFICATION OF BIOLOGICAL TARGETING GROUPS FOR THE TREATMENT OF CANCER | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-04-30 | — | — | US | disclosed |
| US-20090110662-A1 | MODIFICATION OF BIOLOGICAL TARGETING GROUPS FOR THE TREATMENT OF CANCER | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090110662-A1 | MODIFICATION OF BIOLOGICAL TARGETING GROUPS FOR THE TREATMENT OF CANCER | CD44, CD47, EPCAM | IL23R 827/4885RXFP1 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.